Cargando…

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy

Detalles Bibliográficos
Autor principal:	Messing, Edward M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2017
Materias:	Paper Alert
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676756/ https://www.ncbi.nlm.nih.gov/pubmed/29152556 http://dx.doi.org/10.3233/BLC-179023

Ejemplares similares

The BCG Shortage
por: Messing, Edward M.
Publicado: (2017)

Checkpoint Inhibitors for Advanced Bladder Cancer
por: Messing, Edward M.
Publicado: (2016)

Financial Toxicity of Having Bladder Cancer
por: Messing, Edward M.
Publicado: (2018)

Psychological Stress and Suicide in Bladder Cancer Patients
por: Messing, Edward M.
Publicado: (2018)

Perioperative Blood Transfusions and Bladder Cancer Outcomes
por: Messing, Edward M.
Publicado: (2018)

Molecular Landscape of Non-Muscle Invasive Bladder Cancer
por: Messing, Edward M.
Publicado: (2018)

Beyond Cisplatin – I
por: Messing, Edward M.
Publicado: (2016)

A More Thorough Transurethral Resection
por: Messing, Edward M.
Publicado: (2017)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
por: Vilares, Ana T., et al.
Publicado: (2022)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
por: Moreo, Eduardo, et al.
Publicado: (2022)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer
por: Mackel, Charles E, et al.
Publicado: (2016)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

An uncommon cause of miliary disease: intravesical BCG immunotherapy
por: Azevedo, Marcelo, et al.
Publicado: (2021)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Renal Tuberculosis Following Intravesical Bacillus Calmette–Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer
por: Bajramovic, Senad, et al.
Publicado: (2020)

Haemophagocytic lymphohistiocytosis after intravesical BCG administration for bladder cancer presenting with multiorgan failure
por: Liatsos, G. D., et al.
Publicado: (2023)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

Pott’s Disease Caused by Mycobacterium bovis Following Intravesical BCG Therapy for Bladder Cancer
por: Jones, Zachary, et al.
Publicado: (2017)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Differential diagnosis of reactive arthritis in a patient with intravesical BCG immunotherapy
por: Aguridă, Aida Roxana, et al.
Publicado: (2014)

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma
por: Doroud, Delaram, et al.
Publicado: (2022)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

P58. Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer
por: Jallad, S, et al.
Publicado: (2014)

Case Report with Systematic Literature Review on Vascular Complications of BCG Intravesical Therapy for Bladder Cancer
por: King, Brianna, et al.
Publicado: (2022)

BCG in Bladder Cancer Immunotherapy
por: Jiang, Song, et al.
Publicado: (2022)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG
Publicado: (2015)

Pott's disease post intravesical BCG
por: Jain, Anika
Publicado: (2023)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
por: Veeratterapillay, Rajan, et al.
Publicado: (2016)

Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature
por: Oladiran, Oreoluwa, et al.
Publicado: (2020)

Systemic Bacillus Calmette-Guérin (BCG) Infection and Accompanying Warm Autoimmune Haemolytic Anaemia Following Intravesical BCG Immunotherapy
por: Güven, Alper Tuna, et al.
Publicado: (2023)

BCGitis: A rare complication after intravesical BCG therapy
por: Oliveira, Maria João, et al.
Publicado: (2015)

Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
por: Wadhwani, Aman, et al.
Publicado: (2018)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Bladder Cancer Immunotherapy: BCG and Beyond
por: Askeland, Eric J., et al.
Publicado: (2012)

Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?
por: Anastay, Vassili, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_36mph3ead75ql4i5f6fjg3pq9s